Fruquintinib Plus SOX as Neoadjuvant Therapy for Locally Advanced Gastric Adenocarcinoma
NCT05122091
·
clinicaltrials.gov ↗
PHASE2
Phase
UNKNOWN
Status
53
Enrollment
OTHER
Sponsor class
Conditions
Gastric Cancer
GastroEsophageal Cancer
Fruquintinib
SOX
Interventions
DRUG:
Fruquintinib + SOX
Sponsor
Guangxi Medical University